Institutional Ownership
Eyepoint Pharmaceuticals Inc
CUSIP 30233G209COM NEWEYPTQ1 2026
13D / 13G Filings
42
Schedule 13D/13G on record
Beneficial Filers
17
Distinct reporting persons
Largest Stake
16.9%
Max % of class reported
Institutional Holders
180
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
42 filings · latest Feb 24, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 24, 2026 | Paradigm Biocapital Advisors LP | 13G | 5.1% | 92.17M | SEC |
| 2 | Feb 17, 2026 | Tcg Crossover Gp II, LLC | 13G/A | 11.0% | 3.57M | SEC |
| 3 | Feb 12, 2026 | Adage Capital Management, L.P. | 13G/A | 5.7% | 4.70M | SEC |
| 4 | Dec 8, 2025 | Cormorant Asset Management, LP | 13G/A | 10.0% | 8.27M | SEC |
| 5 | Nov 13, 2025 | Adage Capital Management, L.P. | 13G/A | 8.1% | 5.56M | SEC |
| 6 | Oct 17, 2025 | Blackrock, Inc. | 13G/A | 6.5% | 4.49M | SEC |
| 7 | Aug 12, 2025 | Adage Capital Management, L.P. | 13G/A | 9.9% | 6.80M | SEC |
| 8 | Jul 8, 2025 | Federated Hermes, Inc. | 13G/A | 6.7% | 4.60M | SEC |
| 9 | Feb 14, 2025 | Ra Capital Management, L.P. | 13G/A | 4.7% | 3.18M | SEC |
| 10 | Feb 12, 2025 | Adage Capital Management, L.P. | 13G/A | 8.4% | 5.75M | SEC |
32 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Eyepoint Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 8.30M | $106.94M |
| 2 | Cormorant Asset Management, LP | 8.27M | $106.54M |
| 3 | Blackrock, Inc. | 7.18M | $92.52M |
| 4 | Federated Hermes, Inc. | 5.67M | $73.08M |
| 5 | Franklin Resources Inc | 5.05M | $65.08M |
| 6 | Janus Henderson Group PLC | 3.60M | $46.42M |
| 7 | Adage Capital Partners Gp, L.L.C. | 3.30M | $42.54M |
| 8 | Paradigm Biocapital Advisors LP | 3.14M | $40.51M |
| 9 | Commodore Capital LP | 2.83M | $36.41M |
| 10 | State Street Corp | 2.10M | $27.03M |